AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca saphnelo (anifrolumab) — US YoY (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
21.0%
Period ended Jun 30, 2026
Change on a year earlier
-23.0 pts
44.0% in Q2 2025
History
12 quarters
Since Q4 2021
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Saphnelo (anifrolumab) — US YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 21.0% | -23.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 18.0% | -27.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 33.0% | -27.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 42.0% | -13.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 44.0% | -15.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 45.0% | -44.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 60.0% | -20.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 55.0% | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 59.0% | – | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 89.0% | – | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 80.0% | – | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q4 2021 | Dec 31, 2021 | 0.0% | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Saphnelo (anifrolumab) — US YoY (%) (%), quarterly Q4 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_saphnelo_us_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.